MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1	tepotinib Sensitive: A1 - Approval tepotinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1	capmatinib Sensitive: A1 - Approval capmatinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1	savolitinib Sensitive: A1 - Approval savolitinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1	APL-101 Sensitive: A1 - Approval APL-101 Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1	gumarontinib Sensitive: A1 - Approval gumarontinib Sensitive : A1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2	crizotinib Sensitive: A2 - Guideline crizotinib Sensitive : A2
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1
MET exon 14 mutation	Gastric Cancer	MET exon 14 mutation	Gastric Cancer	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2	amivantamab-vmjw Sensitive: C2 – Inclusion Criteria amivantamab-vmjw Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	ensartinib Sensitive: C2 – Inclusion Criteria ensartinib Sensitive : C2	ensartinib Sensitive: C2 – Inclusion Criteria ensartinib Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2	REGN5093 Sensitive: C2 – Inclusion Criteria REGN5093 Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2	BPI-9016M Sensitive: C2 – Inclusion Criteria BPI-9016M Sensitive : C2
MET exon 14 mutation	Solid Tumor	MET exon 14 mutation	Solid Tumor	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2	crizotinib Sensitive: C2 – Inclusion Criteria crizotinib Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2	ABN401 Sensitive: C2 – Inclusion Criteria ABN401 Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2	cabozantinib tablet Sensitive: C2 – Inclusion Criteria cabozantinib tablet Sensitive : C2
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MET exon 14 mutation	Biliary Tract Cancer	MET exon 14 mutation	Biliary Tract Cancer	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3	c-MET inhibitor Sensitive: C3 – Early Trials c-MET inhibitor Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	c-MET inhibitor + Tyrosine kinase inhibitor Resistant: C3 – Early Trials c-MET inhibitor + Tyrosine kinase inhibitor Resistant : C3	c-MET inhibitor + Tyrosine kinase inhibitor Resistant: C3 – Early Trials c-MET inhibitor + Tyrosine kinase inhibitor Resistant : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3	CKD-702 Sensitive: C3 – Early Trials CKD-702 Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	DO-1 Sensitive: C3 – Early Trials DO-1 Sensitive : C3	DO-1 Sensitive: C3 – Early Trials DO-1 Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3	tepotinib + capmatinib Sensitive: C3 – Early Trials tepotinib + capmatinib Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3	PD1 inhibitor Sensitive: C3 – Early Trials PD1 inhibitor Sensitive : C3
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	cabozantinib tablet Sensitive: C4 – Case Studies cabozantinib tablet Sensitive : C4	cabozantinib tablet Sensitive: C4 – Case Studies cabozantinib tablet Sensitive : C4
MET exon 14 mutation	Gastric Cancer	MET exon 14 mutation	Gastric Cancer	S95027 Sensitive: D – Preclinical S95027 Sensitive : D	S95027 Sensitive: D – Preclinical S95027 Sensitive : D
MET exon 14 mutation	Non Small Cell Lung Cancer	MET exon 14 mutation	Non Small Cell Lung Cancer	GB263T Sensitive: D – Preclinical GB263T Sensitive : D	GB263T Sensitive: D – Preclinical GB263T Sensitive : D

MET exon 14 mutation

Associations